Jul. 2 at 6:35 PM
$NUVB “We’re extremely objective about data,” “I’m passionate about my business, but very dispassionate about my data. We just try not to drink our own Kool-Aid. We try to make sure the science is really compelling, makes sense and is rigorously done.” “We won’t work on anything that we don’t think is either first-in-class or best-in-class.. “We’re very disciplined. We’re patient”. Hung said.
So from his own words, Hung only wants best in class drugs in his portfolio. Right now we have Ibtrozi , best in class 50m DOR, then we have Safu, also potential best in class both in low and high glioma.. Then comes DDC platform which i guess also he will create something best in class.. In a previous conference he said that in the first attempt of DDC platform, they had a drug were it had great results but not best in class and that was the reason they didn't continue.. But now they found were was the mistake and they are preparing for a comeback..
Still very cheap !
